Guardant Health (NASDAQ:GH) Raised to "Strong-Buy" at Mizuho

Guardant Health (NASDAQ:GH - Get Free Report) was upgraded by equities researchers at Mizuho to a "strong-buy" rating in a research note issued on Wednesday, April 9th,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. Raymond James reaffirmed an "outperform" rating and set a $59.00 price target (up from $39.00) on shares of Guardant Health in a research note on Friday, February 21st. Guggenheim reiterated a "buy" rating and issued a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Piper Sandler raised their price objective on Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Canaccord Genuity Group boosted their price objective on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a report on Monday, February 24th. Finally, Barclays lowered their target price on shares of Guardant Health from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Twenty equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $49.00.

Guardant Health Trading Down 0.2 %

Shares of NASDAQ GH traded down $0.09 during mid-day trading on Wednesday, reaching $44.76. 543,734 shares of the company's stock were exchanged, compared to its average volume of 2,132,248. Guardant Health has a twelve month low of $15.81 and a twelve month high of $50.89. The firm has a market capitalization of $5.52 billion, a price-to-earnings ratio of -12.57 and a beta of 1.45. The business has a fifty day simple moving average of $43.50 and a 200 day simple moving average of $35.99.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The company had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Equities research analysts predict that Guardant Health will post -2.9 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new position in shares of Guardant Health during the third quarter valued at about $15,624,000. Guyasuta Investment Advisors Inc. purchased a new position in Guardant Health during the fourth quarter worth about $206,000. Geode Capital Management LLC increased its stake in Guardant Health by 1.1% in the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock valued at $64,754,000 after buying an additional 29,686 shares during the last quarter. Entropy Technologies LP purchased a new position in shares of Guardant Health in the 4th quarter worth approximately $377,000. Finally, Raymond James Financial Inc. bought a new position in shares of Guardant Health in the fourth quarter valued at approximately $2,211,000. Institutional investors own 92.60% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.